Mankind Pharma Q4 FY26 Results: Revenue at ₹3,442.93 Cr, Profit at ₹559.42 Cr
Mankind Pharma reported Q4 FY26 consolidated revenue of ₹3,442.93 crore and profit of ₹559.42 crore. For FY26, consolidated revenue was ₹14,277.64 crore and profit was ₹1,938.10 crore. Standalone Q4 revenue was ₹2,581.82 crore with profit at ₹713.61 crore. FY26 standalone revenue was ₹10,421.18 crore and profit was ₹2,037.56 crore.
The announcement contains key financial results for the quarter and full year, which are material information for investors and analysts, significantly impacting the company's valuation and stock performance.
The company reported an increase in revenue and profit for the quarter and year ended March 31, 2026, compared to the previous year, indicating positive financial performance.
Mankind Pharma Limited announced its audited financial results for the quarter and financial year ended March 31, 2026. The company reported consolidated revenue from operations of ₹3,442.93 crore for the fourth quarter, an increase from ₹3,079.37 crore in the same period last year. Profit after exceptional items and tax for the quarter stood at ₹559.42 crore, compared to ₹428.99 crore in the corresponding quarter of the previous fiscal year.
For the full financial year ended March 31, 2026, consolidated revenue from operations was ₹14,277.64 crore, up from ₹12,207.44 crore in FY25. The profit after exceptional items and tax for the full year was ₹1,938.10 crore, a slight decrease from ₹2,006.59 crore in the previous year.
The company also reported standalone financial results. Standalone revenue from operations for the fourth quarter was ₹2,581.82 crore, an increase from ₹2,119.46 crore in Q4 FY25. Standalone profit after exceptional items and tax for the quarter was ₹713.61 crore, up from ₹235.16 crore in the prior year's quarter.
For the full financial year, standalone revenue from operations reached ₹10,421.18 crore, compared to ₹9,507.41 crore in FY25. The standalone profit after exceptional items and tax for the year was ₹2,037.56 crore, an increase from ₹1,724.76 crore in the previous year. The company's net worth as of March 31, 2026, was ₹16,396.94 crore. The audited financial results were approved by the Board of Directors on May 19, 2026.
What to do with a filing like this
Mankind Pharma Limited filed this with the NSE as a statutory disclosure, categorised under quarterly results. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Mankind Pharma Limited. Read the original for the full detail.